Hide metadata

dc.date.accessioned2024-03-04T17:44:35Z
dc.date.available2024-03-04T17:44:35Z
dc.date.created2024-02-09T13:44:32Z
dc.date.issued2023
dc.identifier.citationGainullin, Murat Federico, Lorenzo Osen, Julie Røkke Chaban, Viktoriia Kared, Hassen Alirezaylavasani, Amin Lund-Johansen, Fridtjof Wildendahl, Gull Jacobsen, Jon-Aksel Sarwar Anjum, Hina Stratford, Richard Tennøe, Simen Malone, Brandon Clancy, Trevor Vaage, John T. Henriksen, Kathleen Wüsthoff, Linda Elise Munthe, Ludvig Andre . People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination. Frontiers in Immunology. 2023, 14:1235210, 1-13
dc.identifier.urihttp://hdl.handle.net/10852/108996
dc.description.abstractPeople who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the detrimental effects of opioids on cellular immunity. However, there is limited research on vaccine responses in PWUD, particularly regarding the role that T cells play in the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we show that before vaccination, PWUD did not exhibit an increased frequency of preexisting cross-reactive T cells to SARS-CoV-2 and that, despite the inhibitory effects that opioids have on T-cell immunity, standard vaccination can elicit robust polyfunctional CD4 + and CD8 + T-cell responses that were similar to those found in controls. Our findings indicate that vaccination stimulates an effective immune response in PWUD and highlight targeted vaccination as an essential public health instrument for the control of COVID-19 and other infectious diseases in this group of high-risk patients.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titlePeople who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination
dc.title.alternativeENEngelskEnglishPeople who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination
dc.typeJournal article
dc.creator.authorGainullin, Murat
dc.creator.authorFederico, Lorenzo
dc.creator.authorOsen, Julie Røkke
dc.creator.authorChaban, Viktoriia
dc.creator.authorKared, Hassen
dc.creator.authorAlirezaylavasani, Amin
dc.creator.authorLund-Johansen, Fridtjof
dc.creator.authorWildendahl, Gull
dc.creator.authorJacobsen, Jon-Aksel
dc.creator.authorSarwar Anjum, Hina
dc.creator.authorStratford, Richard
dc.creator.authorTennøe, Simen
dc.creator.authorMalone, Brandon
dc.creator.authorClancy, Trevor
dc.creator.authorVaage, John T.
dc.creator.authorHenriksen, Kathleen
dc.creator.authorWüsthoff, Linda Elise
dc.creator.authorMunthe, Ludvig Andre
cristin.unitcode185,53,18,75
cristin.unitnameK.G. Jebsen senter for B-cellekreft - del UiO
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2244661
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Immunology&rft.volume=14:1235210&rft.spage=1&rft.date=2023
dc.identifier.jtitleFrontiers in Immunology
dc.identifier.volume14
dc.identifier.doihttps://doi.org/10.3389/fimmu.2023.1235210
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1664-3224
dc.type.versionPublishedVersion
cristin.articleid123521
dc.relation.projectNFR/316277
dc.relation.projectSKGJ/KGJ-19
dc.relation.projectHSØ/29286


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International